The Trump administration has issued the final version of a new Medicare payment framework designed to reduce the cost of drugs administered in physicians’ offices, but the policy has been significantly weakened from its initial proposal.
The original model aimed to align Medicare reimbursement rates for these medications with the lower prices paid in other countries. However, the finalized rule appears to have removed or diluted the mechanism that would have directly tied U.S. payments to international benchmarks, effectively reducing the potential impact on drug costs.
Healthcare experts had viewed the overseas pricing comparison as a key tool for curbing Medicare spending on specialty medications. The scaling back of this provision marks a shift in the administration’s approach to negotiating pharmaceutical prices within the healthcare system.
We need transparency here. What specific mechanisms were diluted and why weren’t they included in the final rule?
Surprised they kept any framework at all. Expected a total rollback given the administration’s stance so far.
My doctor bills are already high. I wonder how this change affects average seniors paying out of pocket?
Is this actually about saving money, or just pleasing pharma lobbyists? Seems like a major step backward.
Disappointing. Linking to international prices was the only realistic way to lower these costs for patients.